ProteoNic announces closing of financing round

Leiden, The Netherlands, September 28, 2011 – Dutch biotech company ProteoNic B.V. announces successful completion of a € 6 mln equity financing round led by US-based Fairbanks Investment Fund (FIF), with existing shareholders participating. The funding will be used to accelerate commercialization of ProteoNic’s proprietary UNic™ recombinant protein yield enhancement technology and expand the company’s capabilities in the area of cell line generation and contract services.

ProteoNic and Oxford ET join forces combining UNic™ with flashBAC™ protein expression platform

March 8, 2011 – Leiden, Netherlands/Oxford, United Kingdom – ProteoNic BV, the protein production experts, and Oxford Expression Technologies Ltd (OET), a leading provider of baculovirus-based protein expression products and services, have joined forces in the field of recombinant protein production technology with the aim of jointly offering a superior platform and services. Several projects combining ProteoNic’s UNic™ translation enhancement elements with OET’s flashBAC™ system have been initiated.